Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)

Romain Eschalier, John J V McMurray, Karl Swedberg, Dirk Jan van Veldhuisen, Henry Krum, Stuart J Pocock, Harry Shi, John Vincent, Patrick Rossignol, Faiez Zannad, Bertram Pitt

Research output: Contribution to journalArticleResearchpeer-review

140 Citations (Scopus)

Abstract

The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2 and serum potassium 5.5, >6.0, and 5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events. Eplerenone was effective in reducing the primary composite endpoint in all subgroups. Conclusions In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m2 and potassium
Original languageEnglish
Pages (from-to)1585 - 1593
Number of pages9
JournalJournal of the American College of Cardiology
Volume62
Issue number17
DOIs
Publication statusPublished - 2013

Cite this